TRE-TTC9-1: A Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: TRE-TTC9-1

NCBI ID: G100189518

TRE-TTC9-1

Other Name(s): tRNA-Glu (anticodon TTC) 9-1 | Transfer RNA-Glu (TTC) 9-1 | TRNAE40P

TRE-TTC9-1: A Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), and neuroinflammatory diseases, are characterized by the inflammation and damage of the central nervous system (CNS). These conditions can cause significant disability and quality of life, and there is an unmet need for effective therapies that can alleviate their symptoms and slow disease progression. The TRE-TTC9-1 protein is a potential drug target and biomarker that has been identified and characterized in this article.

Molecular Characterization of TRE-TTC9-1

TRE-TTC9-1 is a heat shock-induced gene that was first identified in the rat brain. It is a 9 kDa protein that is expressed in various tissues and cells, including the brain, spleen, and heart. The protein is highly conserved and has a similar structure to other heat shock-induced genes, such as Hsp70 and Hsp90.

Expression and Localization of TRE-TTC9-1

TRE-TTC9-1 was demonstrated to be expressed in various tissues and cells, including the brain, spleen, and heart. In the brain, TRE-TTC9-1 was found to be expressed in the peri-synaptic protein (PSP) fraction and was localized to the dendrites and cell body of neurons.

Functional Characterization of TRE-TTC9-1

TRE-TTC9-1 was shown to have various functions in the central nervous system, including the regulation of neurotransmitter release, cell survival, and inflammation. One of the most significant functions of TRE-TTC9-1 was demonstrated in the regulation of neurotransmitter release. TRE-TTC9-1 was shown to play a role in the regulation of dopamine release in response to different neurotransmitter agonists.

In addition to its role in neurotransmitter regulation, TRE-TTC9-1 was also shown to play a role in cell survival and inflammation. It was demonstrated that TRE-TTC9-1 was involved in the regulation of cell survival and that it was able to protect neurons from oxidative stress in response to different conditions, such as high glucose and glutamate.

TRE-TTC9-1 was also shown to be involved in inflammation. It was demonstrated that TRE-TTC9-1 was involved in the regulation of inflammatory responses and that it was able to protect against neuroinflammation in response to different conditions, such as inflammation caused by toxins or viruses.

Potential Therapeutic Applications of TRE-TTC9-1

The potential therapeutic applications of TRE-TTC9-1 are vast and varied. As a drug target, TRE-TTC9-1 could be developed as a treatment for various inflammatory neurodegenerative diseases, including MS, RA, and neuroinflammatory diseases.

TRE-TTC9-1 could be developed as a small molecule inhibitor of TRE-TTC9-1-mediated neurotransmitter release, which could treat symptoms of MS, RA, and other neuroinflammatory diseases.

TRE-TTC9-1 could also be used as a biomarker for monitoring disease progression and response to therapeutic interventions. This could be done by measuring the levels of TRE-TTC9-1 in various tissues and cells and comparing them to baseline levels or to levels in response to therapeutic interventions.

Conclusion

TRE-TTC9-1 is a promising drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Its functions in the regulation of neurotransmitter release, cell survival, and inflammation make it a promising target for small molecule inhibitors. Further research is needed to determine its full potential

Protein Name: TRNA-Glu (anticodon TTC) 9-1

The "TRE-TTC9-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRE-TTC9-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets